Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Not sure I like this part...

If the 10Q does fully account for ALL (current and future) J3 settlement revenue, then I can see that the insider blackout should be lifted. If it doesn't, then I can see no reason for lifting it. And there is still the matter of the oversight by Judge Ward, the reasons for which presumably the insiders are privy to. If this were material to PTSC, how could the trading restriction be lifted?

Still way too many unanswered questions, but I'm glad to see the buyback reinstituted.

Share
New Message
Please login to post a reply